{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:22:43Z","timestamp":1790256163517,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012173","name":"China-Japan Friendship Hospital","doi-asserted-by":"publisher","award":["ZRJY2023-GG02"],"award-info":[{"award-number":["ZRJY2023-GG02"]}],"id":[{"id":"10.13039\/501100012173","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08262-3","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T17:55:38Z","timestamp":1779126938000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A new hope with CAR T-cell therapy for refractory idiopathic inflammatory myopathies: a systematic review"],"prefix":"10.1186","volume":"24","author":[{"given":"Xueyan","family":"Shan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengtao","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guochun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3674-9307","authenticated-orcid":false,"given":"Yongpeng","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"issue":"1","key":"8262_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s12016-025-09047-0","volume":"68","author":"T Liu","year":"2025","unstructured":"Liu T, Chen B, Yin G, Xie Q. Targeting B Cells for the Treatment of Idiopathic Inflammatory Myopathy. Clin Rev Allergy Immunol. 2025;68(1):40. https:\/\/doi.org\/10.1007\/s12016-025-09047-0.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"8262_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/2044-5040-3-13","volume":"3","author":"S Rayavarapu","year":"2013","unstructured":"Rayavarapu S, Coley W, Kinder TB, Nagaraju K. Idiopathic inflammatory myopathies: pathogenic mechanisms of muscle weakness. Skelet Muscle. 2013;3(1):13. https:\/\/doi.org\/10.1186\/2044-5040-3-13.","journal-title":"Skelet Muscle"},{"issue":"11","key":"8262_CR3","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1136\/ard-2024-225773","volume":"83","author":"I Pinal-Fernandez","year":"2024","unstructured":"Pinal-Fernandez I, Mu\u00f1oz-Braceras S, Casal-Dominguez M, et al. Pathological autoantibody internalisation in myositis. Ann Rheum Dis. 2024;83(11):1549\u201360. https:\/\/doi.org\/10.1136\/ard-2024-225773.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"8262_CR4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00401-022-02438-z","volume":"144","author":"C Preu\u00dfe","year":"2022","unstructured":"Preu\u00dfe C, Paesler B, Nelke C, et al. Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis. Acta Neuropathol. 2022;144(2):353\u201372. https:\/\/doi.org\/10.1007\/s00401-022-02438-z.","journal-title":"Acta Neuropathol"},{"issue":"7","key":"8262_CR5","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/rheumatology\/keac602","volume":"62","author":"DC Anang","year":"2023","unstructured":"Anang DC, Walter HAW, Lim J, et al. B-cell receptor profiling before and after IVIG monotherapy in newly diagnosed idiopathic inflammatory myopathies. Rheumatology (Oxford). 2023;62(7):2585\u201393. https:\/\/doi.org\/10.1093\/rheumatology\/keac602.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"8262_CR6","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13075-020-02412-8","volume":"23","author":"J Young-Glazer","year":"2021","unstructured":"Young-Glazer J, Cisneros A, Wilfong EM, Smith SA, Crofford LJ, Bonami RH. Jo-1 autoantigen-specific B cells are skewed towards distinct functional B cell subsets in anti-synthetase syndrome patients. Arthritis Res Ther. 2021;23(1):33. https:\/\/doi.org\/10.1186\/s13075-020-02412-8.","journal-title":"Arthritis Res Ther"},{"key":"8262_CR7","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jneuroim.2019.04.014","volume":"332","author":"G Dzangu\u00e9-Tchoupou","year":"2019","unstructured":"Dzangu\u00e9-Tchoupou G, Allenbach Y, Preu\u00dfe C, Stenzel W, Benveniste O. Mass cytometry reveals an impairment of B cell homeostasis in anti-synthetase syndrome. J Neuroimmunol. 2019;332:212\u20135. https:\/\/doi.org\/10.1016\/j.jneuroim.2019.04.014.","journal-title":"J Neuroimmunol"},{"issue":"1","key":"8262_CR8","doi-asserted-by":"publisher","first-page":"102931","DOI":"10.1016\/j.autrev.2021.102931","volume":"21","author":"M Su","year":"2022","unstructured":"Su M, Zhao C, Luo S. Therapeutic potential of chimeric antigen receptor based therapies in autoimmune diseases. Autoimmun Rev. 2022;21(1):102931. https:\/\/doi.org\/10.1016\/j.autrev.2021.102931.","journal-title":"Autoimmun Rev"},{"issue":"22","key":"8262_CR9","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1001\/jama.2024.19462","volume":"332","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Maus MV, Hinrichs CS. CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review. JAMA. 2024;332(22):1924\u201335. https:\/\/doi.org\/10.1001\/jama.2024.19462.","journal-title":"JAMA"},{"issue":"10","key":"8262_CR10","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1111\/head.12246","volume":"53","author":"JJ Gagnier","year":"2013","unstructured":"Gagnier JJ, Kienle G, Altman DG, et al. The CARE Guidelines: Consensus-Based Clinical Case Reporting Guideline Development. Headache: J Head Face Pain. 2013;53(10):1541\u20137.","journal-title":"Headache: J Head Face Pain"},{"issue":"10","key":"8262_CR11","first-page":"2127","volume":"18","author":"Z Munn","year":"2020","unstructured":"Munn Z, Barker TH, Moola S, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synthesis. 2020;18(10):2127\u201333.","journal-title":"JBI Evid Synthesis"},{"issue":"9","key":"8262_CR12","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1093\/rheumatology\/keaf190","volume":"64","author":"I Haase","year":"2025","unstructured":"Haase I, Richter J, Holzer MT, et al. A novel approach to refractory idiopathic inflammatory myopathy: CD19 CAR T-cell therapy\u2014case report and literature review. Rheumatology. 2025;64(9):5101\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/keaf190.","journal-title":"Rheumatology"},{"issue":"6","key":"8262_CR13","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1038\/s41591-025-03718-3","volume":"31","author":"F M\u00fcller","year":"2025","unstructured":"M\u00fcller F, Wirsching A, Hagen M, et al. BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells. Nat Med. 2025;31(6):1793\u20137. https:\/\/doi.org\/10.1038\/s41591-025-03718-3.","journal-title":"Nat Med"},{"issue":"11","key":"8262_CR14","doi-asserted-by":"publisher","first-page":"e312","DOI":"10.1093\/rheumatology\/kead669","volume":"63","author":"J Taubmann","year":"2024","unstructured":"Taubmann J, Knitza J, M\u00fcller F, et al. Comment on: Rescue therapy of anti-synthetase syndrome with CD19-targeted CART cells after failure of several B cell-depleting antibodies: reply. Rheumatology (Oxford). 2024;63(11):e312\u20134. https:\/\/doi.org\/10.1093\/rheumatology\/kead669.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"8262_CR15","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, et al. CD19 CAR T-Cell Therapy in Autoimmune Disease \u2014 A Case Series with Follow-up. N Engl J Med. 2024;390(8):687\u2013700. https:\/\/doi.org\/10.1056\/NEJMoa2308917.","journal-title":"N Engl J Med"},{"key":"8262_CR16","doi-asserted-by":"publisher","unstructured":"Mozaffar T, Naddaf E, Chahin N, et al. OP0316 Reset-myositisTM: clinical trial evaluating rese-cel (resecabtagene autoleucel), a fully human, autologous 4-1BB anti-CD19 CAR T cell therapy in idiopathic inflammatory myopathies. Ann Rheum Dis. 2025;84:254\u20135. https:\/\/doi.org\/10.1016\/j.ard.2025.05.318.","DOI":"10.1016\/j.ard.2025.05.318"},{"issue":"11","key":"8262_CR17","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1016\/j.ymthe.2024.09.009","volume":"32","author":"J Volkov","year":"2024","unstructured":"Volkov J, Nunez D, Mozaffar T, et al. Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I\/II trial. Mol Ther. 2024;32(11):3821\u20138. https:\/\/doi.org\/10.1016\/j.ymthe.2024.09.009.","journal-title":"Mol Ther"},{"issue":"10","key":"8262_CR18","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/art.42933","volume":"76","author":"R Nicolai","year":"2024","unstructured":"Nicolai R, Merli P, Moran Alvarez P, et al. Autologous CD19-Targeting CAR T Cells in a Patient With Refractory Juvenile Dermatomyositis. Arthritis Rheumatol. 2024;76(10):1560\u20135. https:\/\/doi.org\/10.1002\/art.42933.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"8262_CR19","doi-asserted-by":"publisher","first-page":"100676","DOI":"10.1016\/j.medj.2025.100676","volume":"6","author":"A Par\u00eds-Mu\u00f1oz","year":"2025","unstructured":"Par\u00eds-Mu\u00f1oz A, Alcobendas-Rueda RM, Verd\u00fa-S\u00e1nchez C, et al. CD19 CAR-T cell therapy in a pediatric patient with MDA5\u2009+\u2009dermatomyositis and rapidly progressive interstitial lung disease. Med. 2025;6(8):100676. https:\/\/doi.org\/10.1016\/j.medj.2025.100676.","journal-title":"Med"},{"issue":"18","key":"8262_CR20","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","volume":"187","author":"X Wang","year":"2024","unstructured":"Wang X, Wu X, Tan B, et al. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell. 2024;187(18):4890\u2013e49049. https:\/\/doi.org\/10.1016\/j.cell.2024.06.027.","journal-title":"Cell"},{"issue":"6","key":"8262_CR21","doi-asserted-by":"publisher","first-page":"e2315990121","DOI":"10.1073\/pnas.2315990121","volume":"121","author":"C Qin","year":"2024","unstructured":"Qin C, Dong MH, Zhou LQ, et al. Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy. Proc Natl Acad Sci U S A. 2024;121(6):e2315990121. https:\/\/doi.org\/10.1073\/pnas.2315990121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"8262_CR22","doi-asserted-by":"publisher","first-page":"e424","DOI":"10.1016\/S2665-9913(25)00091-8","volume":"7","author":"M Hagen","year":"2025","unstructured":"Hagen M, M\u00fcller F, Wirsching A, et al. Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study. Lancet Rheumat. 2025;7(6):e424\u201333. https:\/\/doi.org\/10.1016\/S2665-9913(25)00091-8.","journal-title":"Lancet Rheumat"},{"key":"8262_CR23","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ard.2025.05.459","volume":"84","author":"M Hagen","year":"2025","unstructured":"Hagen M, Wirsching A, M\u00fcller F, et al. OP0316 Reset-myositis TM: clinical trial evaluating rese-cel (resecabtagene autoleucel), a fully human, autologous 4-1BB anti-CD19 CAR T cell therapy in idiopathic inflammatory myopathies. Ann Rheum Dis. 2025;84:369\u201370. https:\/\/doi.org\/10.1016\/j.ard.2025.05.459.","journal-title":"Ann Rheum Dis"},{"key":"8262_CR24","doi-asserted-by":"publisher","unstructured":"Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95). https:\/\/doi.org\/10.1126\/scitranslmed.3002842.","DOI":"10.1126\/scitranslmed.3002842"},{"issue":"21","key":"8262_CR25","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1182\/blood.2020008936","volume":"137","author":"D Wang","year":"2021","unstructured":"Wang D, Wang J, Hu G, et al. A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma. Blood. 2021;137(21):2890\u2013901. https:\/\/doi.org\/10.1182\/blood.2020008936.","journal-title":"Blood"},{"issue":"2","key":"8262_CR26","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1182\/blood.2023020023","volume":"142","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo F, Becilli M, Rosignoli C, et al. Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed\/refractory BCP-ALL. Blood. 2023;142(2):146\u201357. https:\/\/doi.org\/10.1182\/blood.2023020023.","journal-title":"Blood"},{"key":"8262_CR27","doi-asserted-by":"publisher","first-page":"7200","DOI":"10.1038\/s41467-021-27312-6","volume":"12","author":"M Maschan","year":"2021","unstructured":"Maschan M, Caimi PF, Reese-Koc J, et al. Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients. Nat Commun. 2021;12:7200. https:\/\/doi.org\/10.1038\/s41467-021-27312-6.","journal-title":"Nat Commun"},{"issue":"10","key":"8262_CR28","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, M\u00fcller F, Mougiakakos D, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28(10):2124\u201332. https:\/\/doi.org\/10.1038\/s41591-022-02017-5.","journal-title":"Nat Med"},{"issue":"2","key":"8262_CR29","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1016\/S2665-9913(23)00322-3","volume":"6","author":"CM Connolly","year":"2024","unstructured":"Connolly CM, Gupta L, Fujimoto M, Machado PM, Paik JJ. Idiopathic inflammatory myopathies: current insights and future frontiers. Lancet Rheumatol. 2024;6(2):e115\u201327. https:\/\/doi.org\/10.1016\/S2665-9913(23)00322-3.","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"8262_CR30","doi-asserted-by":"publisher","first-page":"101762","DOI":"10.1016\/j.berh.2022.101762","volume":"36","author":"CM Connolly","year":"2022","unstructured":"Connolly CM, Plomp L, Paik JJ, Allenbach Y. Possible future avenues for myositis therapeutics: DM, IMNM and IBM. Best Pract Res Clin Rheumatol. 2022;36(2):101762. https:\/\/doi.org\/10.1016\/j.berh.2022.101762.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"8262_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/nyas.13577","volume":"1415","author":"M Uzzan","year":"2018","unstructured":"Uzzan M, Ko HM, Rosenstein AK, Pourmand K, Colombel JF, Mehandru S. Efficient long-term depletion of CD20\u2009+\u2009B cells by rituximab does not affect gut-resident plasma cells. Ann N Y Acad Sci. 2018;1415(1):5\u201310. https:\/\/doi.org\/10.1111\/nyas.13577.","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"8262_CR32","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1136\/ard-2024-226142","volume":"84","author":"C Tur","year":"2025","unstructured":"Tur C, Eckstein M, Velden J, et al. CD19-CAR T-cell therapy induces deep tissue depletion of B cells. Ann Rheum Dis. 2025;84(1):106\u201314. https:\/\/doi.org\/10.1136\/ard-2024-226142.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"8262_CR33","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1182\/blood-2014-02-555169","volume":"125","author":"HE Mei","year":"2015","unstructured":"Mei HE, Wirries I, Fr\u00f6lich D, et al. A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow. Blood. 2015;125(11):1739\u201348. https:\/\/doi.org\/10.1182\/blood-2014-02-555169.","journal-title":"Blood"},{"issue":"1","key":"8262_CR34","doi-asserted-by":"publisher","first-page":"2149675","DOI":"10.1002\/eji.202149675","volume":"53","author":"A Merino-Vico","year":"2023","unstructured":"Merino-Vico A, Frazzei G, van Hamburg JP, Tas SW. Targeting B cells and plasma cells in autoimmune diseases: From established treatments to novel therapeutic approaches. Eur J Immunol. 2023;53(1):2149675. https:\/\/doi.org\/10.1002\/eji.202149675.","journal-title":"Eur J Immunol"},{"key":"8262_CR35","doi-asserted-by":"publisher","first-page":"1051609","DOI":"10.3389\/fimmu.2022.1051609","volume":"13","author":"C Zhen","year":"2022","unstructured":"Zhen C, Hou Y, Zhao B, Ma X, Dai T, Yan C. Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis. Front Immunol. 2022;13:1051609. https:\/\/doi.org\/10.3389\/fimmu.2022.1051609.","journal-title":"Front Immunol"},{"issue":"4","key":"8262_CR36","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/art.42784","volume":"76","author":"J Taubmann","year":"2024","unstructured":"Taubmann J, M\u00fcller F, Yalcin Mutlu M, et al. CD19 Chimeric Antigen Receptor T Cell Treatment: Unraveling the Role of B Cells in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2024;76(4):497\u2013504. https:\/\/doi.org\/10.1002\/art.42784.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"8262_CR37","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1038\/s41467-024-46053-w","volume":"15","author":"W Chen","year":"2024","unstructured":"Chen W, Hong SH, Jenks SA, et al. Distinct transcriptomes and autocrine cytokines underpin maturation and survival of antibody-secreting cells in systemic lupus erythematosus. Nat Commun. 2024;15(1):1899. https:\/\/doi.org\/10.1038\/s41467-024-46053-w.","journal-title":"Nat Commun"},{"issue":"20","key":"8262_CR38","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1200\/JCO.21.01676","volume":"40","author":"Y Wang","year":"2022","unstructured":"Wang Y, Cao J, Gu W, et al. Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma. J Clin Oncol. 2022;40(20):2246\u201356. https:\/\/doi.org\/10.1200\/JCO.21.01676.","journal-title":"J Clin Oncol"},{"issue":"11","key":"8262_CR39","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1038\/s41591-025-03937-8","volume":"31","author":"J Feng","year":"2025","unstructured":"Feng J, Huo D, Hong R, et al. Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial. Nat Med. 2025;31(11):3725\u201336. https:\/\/doi.org\/10.1038\/s41591-025-03937-8.","journal-title":"Nat Med"},{"issue":"10","key":"8262_CR40","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/ard-2024-225785","volume":"83","author":"W Wang","year":"2024","unstructured":"Wang W, He S, Zhang W, et al. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann Rheum Dis. 2024;83(10):1304\u201314. https:\/\/doi.org\/10.1136\/ard-2024-225785.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"8262_CR41","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/art.42784","volume":"76","author":"J Taubmann","year":"2024","unstructured":"Taubmann J, M\u00fcller F, Yalcin Mutlu M, et al. CD19 Chimeric Antigen Receptor T Cell Treatment: Unraveling the Role of B Cells in Systemic Lupus Erythematosus. Arthritis Rheumatol. 2024;76(4):497\u2013504. https:\/\/doi.org\/10.1002\/art.42784.","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"8262_CR42","doi-asserted-by":"publisher","first-page":"e179433","DOI":"10.1172\/jci.insight.179433","volume":"9","author":"A Wilhelm","year":"2024","unstructured":"Wilhelm A, Chambers D, M\u00fcller F, et al. Selective CAR T cell-mediated B cell depletion suppresses IFN signature in SLE. JCI Insight. 2024;9(12):e179433. https:\/\/doi.org\/10.1172\/jci.insight.179433.","journal-title":"JCI Insight"},{"issue":"6","key":"8262_CR43","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1016\/S2665-9913(24)00377-1","volume":"7","author":"M Scherlinger","year":"2025","unstructured":"Scherlinger M, Nocturne G, Radic M, et al. CAR T-cell therapy in autoimmune diseases: where are we and where are we going? Lancet Rheumatol. 2025;7(6):e434\u201347. https:\/\/doi.org\/10.1016\/S2665-9913(24)00377-1.","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"8262_CR44","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s12016-025-09113-7","volume":"68","author":"M Freeley","year":"2025","unstructured":"Freeley M. CAR T Cell Therapy for Rheumatoid Arthritis. Clin Rev Allergy Immunol. 2025;68(1):100. https:\/\/doi.org\/10.1007\/s12016-025-09113-7.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"8262_CR45","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","volume":"7","author":"IE Lundberg","year":"2021","unstructured":"Lundberg IE, Fujimoto M, Vencovsky J, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021;7(1):86. https:\/\/doi.org\/10.1038\/s41572-021-00321-x.","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"8262_CR46","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","volume":"30","author":"DM Cordas Dos Santos","year":"2024","unstructured":"Cordas Dos Santos DM, Tix T, Shouval R, et al. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat Med. 2024;30(9):2667\u201378. https:\/\/doi.org\/10.1038\/s41591-024-03084-6.","journal-title":"Nat Med"},{"issue":"1","key":"8262_CR47","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/cancers13010038","volume":"13","author":"AS Davey","year":"2020","unstructured":"Davey AS, Call ME, Call MJ. The Influence of Chimeric Antigen Receptor Structural Domains on Clinical Outcomes and Associated Toxicities. Cancers (Basel). 2020;13(1):38. https:\/\/doi.org\/10.3390\/cancers13010038.","journal-title":"Cancers (Basel)"},{"key":"8262_CR48","doi-asserted-by":"publisher","first-page":"152786","DOI":"10.1016\/j.semarthrit.2025.152786","volume":"74","author":"A Nordmann-Gomes","year":"2025","unstructured":"Nordmann-Gomes A, Khalili L, Tang W, et al. CAR T-cell therapy in SLE: A systematic review. Semin Arthritis Rheum. 2025;74:152786. https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152786.","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"8262_CR49","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","volume":"54","author":"S Fried","year":"2019","unstructured":"Fried S, Avigdor A, Bielorai B, et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transpl. 2019;54(10):1643\u201350. https:\/\/doi.org\/10.1038\/s41409-019-0487-3.","journal-title":"Bone Marrow Transpl"},{"key":"8262_CR50","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3389\/fimmu.2020.00524","volume":"11","author":"RD Sandler","year":"2020","unstructured":"Sandler RD, Tattersall RS, Schoemans H, et al. Diagnosis and Management of Secondary HLH\/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP). Front Immunol. 2020;11:524. https:\/\/doi.org\/10.3389\/fimmu.2020.00524.","journal-title":"Front Immunol"},{"key":"8262_CR51","doi-asserted-by":"publisher","first-page":"1519671","DOI":"10.3389\/fimmu.2024.1519671","volume":"15","author":"Y Kong","year":"2025","unstructured":"Kong Y, Li J, Zhao X, Wu Y, Chen L. CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity. Front Immunol. 2025;15:1519671. https:\/\/doi.org\/10.3389\/fimmu.2024.1519671.","journal-title":"Front Immunol"},{"key":"8262_CR52","doi-asserted-by":"publisher","unstructured":"Gao J, Li M, Sun M et al. Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China. Lancet. 2025:S0140-6736(25)01671-X. https:\/\/doi.org\/10.1016\/S0140-6736(25)01671-X.","DOI":"10.1016\/S0140-6736(25)01671-X"},{"issue":"16","key":"8262_CR53","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1016\/j.cell.2025.05.038","volume":"188","author":"X Wang","year":"2025","unstructured":"Wang X, Zhang Y, Jin Y, et al. An iPSC-derived CD19\/BCMA CAR-NK therapy in a patient with systemic sclerosis. Cell. 2025;188(16):4225\u2013e423812. https:\/\/doi.org\/10.1016\/j.cell.2025.05.038.","journal-title":"Cell"},{"issue":"2","key":"8262_CR54","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3390\/biomedicines10020287","volume":"10","author":"M Arjomandnejad","year":"2022","unstructured":"Arjomandnejad M, Kopec AL, Keeler AM. CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications. Biomedicines. 2022;10(2):287. https:\/\/doi.org\/10.3390\/biomedicines10020287.","journal-title":"Biomedicines"},{"key":"8262_CR55","doi-asserted-by":"publisher","first-page":"102961","DOI":"10.1016\/j.jaut.2022.102961","volume":"134","author":"DA Boardman","year":"2023","unstructured":"Boardman DA, Wong MQ, Rees WD, et al. Flagellin-specific human CAR Tregs for immune regulation in IBD. J Autoimmun. 2023;134:102961. https:\/\/doi.org\/10.1016\/j.jaut.2022.102961.","journal-title":"J Autoimmun"},{"issue":"1","key":"8262_CR56","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1038\/s41467-024-46448-9","volume":"15","author":"M Doglio","year":"2024","unstructured":"Doglio M, Ugolini A, Bercher-Brayer C, et al. Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus. Nat Commun. 2024;15(1):2542. https:\/\/doi.org\/10.1038\/s41467-024-46448-9.","journal-title":"Nat Commun"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08262-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08262-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08262-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:02:25Z","timestamp":1783954945000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08262-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8262"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08262-3","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"890"}}